GO
Loading...

Pharmaceuticals

More

  • German drugmaker Merck said Thursday its fourth-quarter profit rose 18% after the company boosted sales of its Erbitux cancer treatment.

  • Jan. 22: Two, Too Much to Cover Wednesday, 17 Jan 2007 | 1:54 PM ET

    As we get into the thick of earnings season, next Monday is shaping up to be a big news day for big pharma. Before the bell Pfizer will put out its press release with its 2006 and fourth-quarter numbers.  Then, at 1 p.m. ET the company is holding an analyst meeting in midtown Manhattan where "The Wall Street Journal" reports Pfizer will announce more job cuts and other changes in the way it does business  ...  Meantime, in lower Manhattan the patent trial over Bristol-Myers Squibb's blockbuster bloodthinner Plavix gets underway on Monday morning ... And, finally, opening arguments are set for Monday morning in the two-in-one Vioxx trial in Atlantic City ...

  • Pfizer Prepares Major Overhaul, Buys Stake in Genizon Tuesday, 16 Jan 2007 | 11:21 AM ET

    Pfizer's new chief executive is preparing a plan to overhaul the drug maker that could include cutting several thousand jobs and changing the way it develops, makes and markets medicines, The Wall Street Journal reported on Tuesday.

  • Drugmaker Schwarz Pharma Gets Nod for Parkinson's Drug Tuesday, 16 Jan 2007 | 8:35 AM ET

    Drug maker Schwarz Pharma said Tuesday that its Neupro treatment for Parkinson's disease has received approval in Europe to treat the illness in its advanced stages.

  • Day Ahead: Earnings, OPEC and BP Safety Report Tuesday, 16 Jan 2007 | 8:22 AM ET

    Lots of corporate headlines are already getting attention ahead of the open. Stocks in the U.S. are lining up to open higher at this point, and earnings will be the big focus. After making gains yesterday, European stocks are mixed with a flattish performance, and Japanese stocks were little changed to the downside.

  • CNBC's Domm: A Very Busy Week Ahead Sunday, 14 Jan 2007 | 11:33 AM ET

    Financials and techs, two groups that pulled in the money last week, will be out in front of the news this week when earnings season is in full swing. Markets will also be watching key economic data, a parade of Fed speakers and whatever side show goes on when oil markets reopen, after last week's near six percent slide in crude.

  • President Bush renewed his veto threat today as the House of Representatives passed legislation that would require the government to negotiate drug prices for Medicare patients.

  • Retail Analysis: Good Growth Making A Soft Landing? Friday, 12 Jan 2007 | 10:25 AM ET

    Even though the lights are packed away and the tree has been stripped bare, Santa brought one last gift to investors today. New data shows holiday shopping was more robust than Wall Street had expected. The U.S. Commerce Department reported retail sales rose 0.9% in December, that’s the strongest increase in 5 months.

  • Mylan CEO: We're World Leader in Generic Drugs Tuesday, 9 Jan 2007 | 3:04 PM ET

    More than $18 billion in pharmaceutical drugs are scheduled to go off-patent this year, and consequently medication makers are getting lots of attention from Wall Street. One company expected to benefit from patent expiration is generic drug manufacturer Mylan Labs. CNBC's Mike Huckman caught up with CEO Robert Coury at the JPMorgan Healthcare Conference in San Francisco.

  • Amylin Feeling Pressure From Competition Tuesday, 9 Jan 2007 | 11:34 AM ET
    Amylin

    Amylin Pharmaceuticals has felt the pressure of late since Merck released a diabetes drug to rival its own Byetta. And there’s no relief in sight with Novartis not far behind in getting approval for its Galvus treatment. CNBC’s Mike Huckman spoke with Amylin CEO Ginger Graham about how the competition is affecting the company.

  • The U.S. Supreme Court sided with MedImmune and reinstated the company's lawsuit challenging the validity of a key Genentech patent.

  • Celgene CEO Barer: EPS Down For Q4 Tuesday, 9 Jan 2007 | 10:32 AM ET

    As we've said--CNBC pharmaceuticals reporter Mike Huckman is at the 25th Annual JPMorgan Healthcare Conference in San Francisco this week. This morning on “Squawk on the Street” he got a chance to talk to Celgene Chairman and CEO Sol Barer. Barer’s company is up 365% over the past three years and has a cancer-fighting drug he says has “multibillion-dollar potential.” 

  • You’ll find some of the most influential figures in modern healthcare in San Francisco today, gathered together for the 25th Annual J.P. Morgan Healthcare Conference.  This year, 6500 people are attending, including CNBC’s Mike Huckman who is sifting through volumes of data. In a  "First on CNBC,"  Huckman spoke with James Sabry, M.D./Ph. D., the CEO of Cytokinetics. 

  • CNBC'S Domm: A Real "News Feast" Next Week Friday, 5 Jan 2007 | 9:43 PM ET

    Financial markets will have plenty of news to feast on in the coming week although the markets generated enough headlines on their own in the first days of January with just a few big stories to chew on. The second week of January is quite busy. We're looking forward to some of the most important and newsy industry conferences of the year, plus the start of earnings season, an important Fed speech, and some fresh economic data.

  • Hope Remains for Genentech Cancer Drug Friday, 5 Jan 2007 | 12:22 PM ET

    An ovarian cancer drug under development by Genentech that many investors had written off showed promise in a midstage trial, even though the trial may not have met its main goal.

  • CNBC’s Schacknow: It’s All About the Video Thursday, 4 Jan 2007 | 1:51 PM ET

    If you’ve been extremely bored and somehow stumbled across my bio on the cnbc.com site, you’ll note that I have an extensive background in radio. Radio, as many have noted, has no pictures and is beautiful in its simplicity. TV, on the other hand, is nothing without pictures.

  • BioCryst Pharmaceuticals has won a $102.6 million government contract for advanced development of its influenza antiviral drug, peramivir.

  • Schering-Plough, OraSure to Develop Hepatitis C Test Thursday, 4 Jan 2007 | 12:19 PM ET

    Schering-Plough and OraSure Technologies said they have entered a two-year deal to jointly develop and market a rapid oral test for the detection of hepatitis C virus antibodies.

  • Eli Lilly said it entered into settlement agreements with 14 groups involved in Zyprexa liability suits and will take a fourth-quarter charge of up to $500 million related to the litigation.

  • California Here I Come ... Again Wednesday, 3 Jan 2007 | 3:22 PM ET

    Just got back from a glorious trip to Pasadena where the outcome for my Trojans (apologies to any Michigan Wolverine fans reading this) was much better this year than last. And in a few days, we'll be heading back West to San Francisco to cover the JPMorgan Healthcare Conference which starts next Monday. This year, more than 300 companies will be presenting to nearly 7,000 attendees. That makes it the biggest healthcare investment conference...